OCTOCRYLENE, ZINC OXIDE

N/A

Manufactured by WALMART INC

521 FDA adverse event reports analyzed

Last updated: 2026-04-15

About OCTOCRYLENE, ZINC OXIDE

OCTOCRYLENE, ZINC OXIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by WALMART INC. The most commonly reported adverse reactions for OCTOCRYLENE, ZINC OXIDE include DRUG INEFFECTIVE, FATIGUE, PRODUCT USE ISSUE, DYSPNOEA, CHRONIC KIDNEY DISEASE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for OCTOCRYLENE, ZINC OXIDE.

Top Adverse Reactions

DRUG INEFFECTIVE18 reports
FATIGUE15 reports
PRODUCT USE ISSUE15 reports
DYSPNOEA14 reports
CHRONIC KIDNEY DISEASE11 reports
CONSTIPATION11 reports
DIZZINESS11 reports
HEADACHE11 reports
PAIN11 reports
ANXIETY10 reports
ARTHRALGIA10 reports
FALL10 reports
NAUSEA10 reports
RENAL FAILURE10 reports
ACUTE KIDNEY INJURY9 reports
DEPRESSION9 reports
WEIGHT INCREASED9 reports
COUGH8 reports
PAIN IN EXTREMITY8 reports
WEIGHT DECREASED8 reports
ABDOMINAL PAIN UPPER7 reports
INSOMNIA7 reports
OFF LABEL USE7 reports
VOMITING7 reports
ABDOMINAL DISCOMFORT6 reports
ASTHENIA6 reports
DIARRHOEA6 reports
DRUG DOSE OMISSION6 reports
EYE IRRITATION6 reports
GASTROOESOPHAGEAL REFLUX DISEASE6 reports
HYPERSENSITIVITY6 reports
PRURITUS6 reports
RASH6 reports
ABDOMINAL PAIN5 reports
BACK PAIN5 reports
BLOOD CHOLESTEROL INCREASED5 reports
BLOOD PRESSURE INCREASED5 reports
BODY HEIGHT DECREASED5 reports
HYPERTENSION5 reports
INTENTIONAL PRODUCT MISUSE5 reports
MALAISE5 reports
MUSCLE SPASMS5 reports
PNEUMONIA5 reports
SOMNOLENCE5 reports
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS5 reports
DRUG HYPERSENSITIVITY4 reports
EYE PRURITUS4 reports
GAIT DISTURBANCE4 reports
IMPAIRED DRIVING ABILITY4 reports
INCORRECT DOSE ADMINISTERED4 reports
INCORRECT DRUG ADMINISTRATION DURATION4 reports
MUSCULAR WEAKNESS4 reports
NASOPHARYNGITIS4 reports
PRODUCT QUALITY ISSUE4 reports
THERAPY CESSATION4 reports
VISION BLURRED4 reports
ABDOMINAL DISTENSION3 reports
ALOPECIA3 reports
CEREBROVASCULAR ACCIDENT3 reports
CHEST PAIN3 reports
DECREASED APPETITE3 reports
DEHYDRATION3 reports
DRY MOUTH3 reports
DYSGEUSIA3 reports
DYSPEPSIA3 reports
FEELING ABNORMAL3 reports
FLATULENCE3 reports
GENERAL PHYSICAL HEALTH DETERIORATION3 reports
HEART RATE INCREASED3 reports
HYPOTENSION3 reports
INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION3 reports
INJECTION SITE ERYTHEMA3 reports
INJURY3 reports
INTESTINAL OBSTRUCTION3 reports
LOSS OF CONSCIOUSNESS3 reports
MUSCULOSKELETAL STIFFNESS3 reports
MYOCARDIAL INFARCTION3 reports
NEPHROGENIC ANAEMIA3 reports
OEDEMA PERIPHERAL3 reports
OVERDOSE3 reports
PALPITATIONS3 reports
POOR QUALITY SLEEP3 reports
THROAT IRRITATION3 reports
TREMOR3 reports
URTICARIA3 reports
ACTIVITIES OF DAILY LIVING IMPAIRED2 reports
ACUTE RESPIRATORY FAILURE2 reports
ADVERSE DRUG REACTION2 reports
APPLICATION SITE ERYTHEMA2 reports
APPLICATION SITE PRURITUS2 reports
ARTHRITIS2 reports
ATRIAL FIBRILLATION2 reports
BILIARY DYSKINESIA2 reports
BIPOLAR DISORDER2 reports
BLOOD GLUCOSE INCREASED2 reports
BURNING SENSATION2 reports
CARDIAC DISORDER2 reports
CARDIAC FAILURE2 reports
CARDIAC FAILURE CONGESTIVE2 reports
CARDIAC FLUTTER2 reports

Report Outcomes

Out of 228 classified reports for OCTOCRYLENE, ZINC OXIDE:

Serious 45.2%Non-Serious 54.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female149 (67.1%)
Male73 (32.9%)

Reports by Age

Age 588 reports
Age 576 reports
Age 706 reports
Age 726 reports
Age 766 reports
Age 806 reports
Age 625 reports
Age 755 reports
Age 795 reports
Age 815 reports
Age 825 reports
Age 544 reports
Age 594 reports
Age 654 reports
Age 694 reports
Age 834 reports
Age 273 reports
Age 443 reports
Age 603 reports
Age 613 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with OCTOCRYLENE, ZINC OXIDE?

This profile reflects 521 FDA FAERS reports that mention OCTOCRYLENE, ZINC OXIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for OCTOCRYLENE, ZINC OXIDE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, FATIGUE, PRODUCT USE ISSUE, DYSPNOEA, CHRONIC KIDNEY DISEASE, CONSTIPATION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures OCTOCRYLENE, ZINC OXIDE?

Labeling and FAERS entries often list WALMART INC in connection with OCTOCRYLENE, ZINC OXIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.